Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Prothena Corporation plc is a biotechnology business based in the US. Prothena Corporation shares (PRTA) are listed on the NASDAQ and all prices are listed in US Dollars. Prothena Corporation employs 66 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$62.67|
|52-week range||$10.72 - $79.75|
|50-day moving average||$70.65|
|200-day moving average||$49.70|
|Wall St. target price||$83.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.71|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||0.03%|
|1 month (2021-09-27)||-19.02%|
|3 months (2021-07-27)||30.02%|
|6 months (2021-04-27)||149.28%|
|1 year (2020-10-26)||452.16%|
|2 years (2019-10-25)||629.57%|
|3 years (2018-10-26)||404.59%|
|5 years (2016-10-26)||21.85%|
Valuing Prothena Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Prothena Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Prothena Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Prothena Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$60.7 million|
|Gross profit TTM||$-74,031,000|
|Return on assets TTM||-10.01%|
|Return on equity TTM||-26.93%|
|Market capitalisation||$2.8 billion|
TTM: trailing 12 months
There are currently 1.5 million Prothena Corporation shares held short by investors – that's known as Prothena Corporation's "short interest". This figure is 5.8% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Prothena Corporation shares can be evaluated.
Prothena Corporation's "short interest ratio" (SIR) is the quantity of Prothena Corporation shares currently shorted divided by the average quantity of Prothena Corporation shares traded daily (recently around 372393.76558603). Prothena Corporation's SIR currently stands at 4.01. In other words for every 100,000 Prothena Corporation shares traded daily on the market, roughly 4010 shares are currently held short.
However Prothena Corporation's short interest can also be evaluated against the total number of Prothena Corporation shares, or, against the total number of tradable Prothena Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prothena Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Prothena Corporation shares in existence, roughly 30 shares are currently held short) or 0.0428% of the tradable shares (for every 100,000 tradable Prothena Corporation shares, roughly 43 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Prothena Corporation.
Find out more about how you can short Prothena Corporation stock.
We're not expecting Prothena Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Prothena Corporation's shares have ranged in value from as little as $10.72 up to $79.749. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Prothena Corporation's is 1.4524. This would suggest that Prothena Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.